Fundz
Back to SEC Filings

Watching Protagenic Therapeutics, Inc.\new? See every signal: funding, hires, M&A, contracts, sentiment.

Book a demoChoose your plan
10-KHIGH RiskDETERIORATING

Protagenic Therapeutics, Inc.\new

Filed: Aug 14, 2026 CIK: 0001022899
View original filing on SEC.gov

AI Executive Summary

AI-powered analysis of 10-K filing content

Protagenic is a clinical-stage biopharmaceutical company with no approved products or revenue, facing a going concern issue with cash sufficient only until the end of Q3 2026. The company recently unwound a reverse merger with Phytanix Bio amid litigation (now settled), which severely complicates financial comparability and reflects governance turmoil. Internal controls over financial reporting were deemed ineffective, citing material weaknesses including lack of segregation of duties concentrated in the Executive Chairman.

Red Flags Detected (7)

Going concern doubt explicitly disclosed; cash runway only through Q3 2026

Internal control over financial reporting deemed not effective due to material weaknesses

Heavy reliance on Executive Chairman for nearly all key financial duties with access to all financial information

4 more red flags detected

Key Takeaways

Company is a clinical-stage biopharma with lead candidate PT00114 (TCAP-1) still in Phase 1, with Phase 2 not expected until late 2026

No revenue-generating products; entirely dependent on external financing to continue operations

3 more takeaways

Filing Overview

Form TypeAnnual Report (10-K)
Filing DateAug 14, 2026
Risk LevelHIGH
TrendDETERIORATING
AI Confidence85%
Red Flags7

What This Means

High Risk Filing: This company is showing signs of financial stress or significant operational challenges.

Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.

Annual Report: Comprehensive filing covering the full fiscal year with audited financial statements.

View Full Filing on SEC.govBrowse More Filings